Bertram L, Tanzi RE. Alzheimer disease risk genes: 29 and counting. Nat Rev Neurol. 2019;15:191–2.
Tanzi RE, Bertram L. Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell. 2005;120:545–55.
Griciuc A, Tanzi RE. The role of innate immune genes in Alzheimer’s disease. Curr Opin Neurol. 2021;34:228–36.
Knopman DS, Amieva H, Petersen RC, Chételat G, Holtzman DM, Hyman BT, et al. Alzheimer disease. Nat Rev Dis Primers. 2021;7:33.
Veitch DP, Weiner MW, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. Understanding disease progression and improving Alzheimer’s disease clinical trials: recent highlights from the Alzheimer’s Disease Neuroimaging Initiative. Alzheimer’s Dementia. 2018;15:106–52.
Bertram L, Tanzi RE. Alzheimer disease risk genes: 29 and counting. Nat Rev Neurol. 2019;15:1.
Chhatwal JP, Schultz SA, McDade E, Schultz AP, Liu L, Hanseeuw BJ, et al. Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer’s disease: cross-sectional and longitudinal analyses of an observational study. Lancet Neurol. 2022;21:140–52.
Dujardin S, Commins C, Lathuiliere A, Beerepoot P, Fernandes AR, Kamath TV, et al. Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease. Nat Med. 2020;26:1256–63.
Das SR, Lyu X, Duong MT, Xie L, McCollum L, Flores R, et al. Tau-atrophy variability reveals phenotypic heterogeneity in Alzheimer’s disease. Ann Neurol. 2021;90:751–62.
Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan MF, et al. Genome-wide association analysis reveals putative Alzheimer’s disease susceptibility loci in addition to APOE. Am J Hum Genetics. 2008;83:623–32.
Hollingworth P, Harold D, Sims R, Gerrish A, Lambert J-C, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet. 2011;43:429–35.
Naj AC, Jun G, Beecham GW, Wang L-S, Vardarajan BN, Buros J, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet. 2011;43:436–41.
Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer’s disease. New Engl J Medicine. 2013;368:117–27.
Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. New Engl J Med. 2013;368:107–16.
Johansson JU, Brubaker WD, Javitz H, Bergen AW, Nishita D, Trigunaite A, et al. Peripheral complement interactions with amyloid β peptide in Alzheimer’s disease: polymorphisms, structure, and function of complement receptor 1. Alzheimer’s Dementia. 2018;14:1438–49.
Rogers J, Li R, Mastroeni D, Grover A, Leonard B, Ahern G, et al. Peripheral clearance of amyloid β peptide by complement C3-dependent adherence to erythrocytes. Neurobiol Aging. 2006;27:1733–9.
Crehan H, Hardy J, Pocock J. Blockage of CR1 prevents activation of rodent microglia. Neurobiol Dis. 2013;54:139–49.
Crehan H, Holton P, Wray S, Pocock J, Guerreiro R, Hardy J. Complement receptor 1 (CR1) and Alzheimer’s disease. Immunobiology. 2012;217:244–50.
Efthymiou AG, Goate AM. Late onset Alzheimer’s disease genetics implicates microglial pathways in disease risk. Mol Neurodegener. 2017;12:43.
Taylor RP, Lindorfer MA, Atkinson JP. Clearance of amyloid-beta with bispecific antibody constructs bound to erythrocytes. Alzheimer’s Dementia Transl Res Clin Interventions. 2020;6: e12067.
Ryan J, Fransquet P, Wrigglesworth J, Lacaze P. Phenotypic heterogeneity in dementia: a challenge for epidemiology and biomarker studies. Front Public Heal. 2018;6:181.
Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nat Genet. 2019;51:404–13.
Redondo-García S, Peris-Torres C, Caracuel-Peramos R, Rodríguez-Manzaneque JC. ADAMTS proteases and the tumor immune microenvironment: lessons from substrates and pathologies. Matrix Biology Plus. 2020;9:100054.
Mazzon C, Anselmo A, Soldani C, Cibella J, Ploia C, Moalli F, et al. Agrin is required for survival and function of monocytic cells. Blood. 2012;119:5502–11.
Lambert J-C, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet. 2009;41:1094–9.
Borucki DM, Toutonji A, Couch C, Mallah K, Rohrer B, Tomlinson S. Complement-mediated microglial phagocytosis and pathological changes in the development and degeneration of the visual system. Front Immunol. 2020;11:566892.
Agrawal V, Sawhney N, Hickey E, McCarthy JV. Loss of Presenilin 2 function is associated with defective LPS-mediated innate immune responsiveness. Mol Neurobiol. 2016;53:3428–38.
Nam H, Lee Y, Kim B, Lee J-W, Hwang S, An H-K, et al. Presenilin 2 N141I mutation induces hyperactive immune response through the epigenetic repression of REV-ERBα. Nat Commun. 2022;13:1972.
Fung S, Smith CL, Prater KE, Case A, Green K, Osnis L, et al. Early-onset familial Alzheimer disease variant PSEN2 N141I heterozygosity is associated with altered microglia phenotype. J Alzheimer’s Dis. 2020;77:675–88.
Mendez MF. Early-onset Alzheimer disease. Neurol Clin. 2017;35:263–81.
Bellenguez C, Küçükali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat Genet. 2022;54(4):412–36.
Herda S, Raczkowski F, Mittrücker H-W, Willimsky G, Gerlach K, Kühl AA, et al. The sorting receptor sortilin exhibits a dual function in exocytic trafficking of Interferon-γ and Granzyme A in T cells. Immunity. 2012;37:854–66.
Mortensen MB, Kjolby M, Gunnersen S, Larsen JV, Palmfeldt J, Falk E, et al. Targeting sortilin in immune cells reduces proinflammatory cytokines and atherosclerosis. J Clin Invest. 2014;124:5317–22.
Lambrecht BN, Vanderkerken M, Hammad H. The emerging role of ADAM metalloproteinases in immunity. Nat Rev Immunol. 2018;18:745–58.
Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303:1832–40.
Sudwarts A, Ramesha S, Gao T, Ponnusamy M, Wang S, Hansen M, et al. BIN1 is a key regulator of proinflammatory and neurodegeneration-related activation in microglia. Mol Neurodegener. 2022;17:33.
Nordhoff C, Hillesheim A, Walter BM, Haasbach E, Planz O, Ehrhardt C, et al. The adaptor protein FHL2 enhances the cellular innate immune response to influenza A virus infection. Cell Microbiol. 2012;14:1135–47.
Wixler V. The role of FHL2 in wound healing and inflammation. Faseb J. 2019;33:7799–809.
(EADI) EADI, (GERAD) G and ER in AD, (ADGC) ADGC, (CHARGE) C for H and AR in GE, Lambert J-C, Ibrahim-Verbaas CA, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet. 2013;45:1452–8.
Itakura J, Sato M, Ito T, Mino M, Fushimi S, Takahashi S, et al. Spred2-deficiecy protects mice from polymicrobial septic peritonitis by enhancing inflammation and bacterial clearance. Sci Rep-uk. 2017;7:12833.
Ishikawa E, Kosako H, Yasuda T, Ohmuraya M, Araki K, Kurosaki T, et al. Protein kinase D regulates positive selection of CD4+ thymocytes through phosphorylation of SHP-1. Nat Commun. 2016;7:12756.
Brigas HC, Ribeiro M, Coelho JE, Gomes R, Gomez-Murcia V, Carvalho K, et al. IL-17 triggers the onset of cognitive and synaptic deficits in early stages of Alzheimer’s disease. Cell Rep. 2021;36:109574.
Girondel C, Meloche S. Interleukin-17 receptor D in physiology, inflammation and cancer. Frontiers Oncol. 2021;11:656004.
Schulte-Schrepping J, Reusch N, Paclik D, Baßler K, Schlickeiser S, Zhang B, et al. Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell. 2020;182:1419-1440.e23.
Utting O, Sedgmen BJ, Watts TH, Shi X, Rottapel R, Iulianella A, et al. Immune functions in mice lacking Clnk, an SLP-76-related adaptor expressed in a subset of immune cells. Mol Cell Biol. 2004;24:6067–75.
Gu Y, Chae H-D, Siefring JE, Jasti AC, Hildeman DA, Williams DA. RhoH GTPase recruits and activates Zap70 required for T cell receptor signaling and thymocyte development. Nat Immunol. 2006;7:1182–90.
留言 (0)